Nektar Therapeutics (NKTR) Current Assets (2010 - 2026)

Nektar Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $589.0 million for Q1 2026.

• In Q1 2026, Current Assets rose 156.2% year-over-year to $589.0 million; the TTM figure through Mar 2026 stood at $589.0 million (up 156.2% YoY), while the FY2025 annual figure was $266.3 million, up 1.9% from the prior year.
• Current Assets was $589.0 million for Q1 2026 at Nektar Therapeutics, up from $266.3 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $733.5 million in Q1 2022 to a low of $186.6 million in Q2 2025.
• Historically, Current Assets has averaged $407.2 million across 5 years, with a median of $330.7 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Current Assets slumped 39.43% in 2023, then surged 156.2% in 2026.
• A 5-year view of Current Assets shows it stood at $546.0 million in 2022, then plunged by 39.43% to $330.7 million in 2023, then declined by 20.99% to $261.3 million in 2024, then rose by 1.9% to $266.3 million in 2025, then soared by 121.22% to $589.0 million in 2026.
• The last three Current Assets figures came in at $589.0 million (Q1 2026), $266.3 million (Q4 2025), and $281.4 million (Q3 2025), per Business Quant data.